Lisocabtagene maraleucel is a type of CAR T-cell therapy that is composed of genetically modified T-cells from the patient, which are directed against CD19.
The drug is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma that have received prior therapy.